Norethindrone Acetate/Ethinyl Estradiol · Kit · Millicent US, Inc.
NDC 72495-0601-84 · 3 POUCH in 1 CARTON / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACK · NDA · View full market →
6 companies supply this market — a reasonable cushion if one runs into trouble. Generic versions run $0.2634 per unit — 27× cheaper. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 4 quarters since 2024.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NP | Jul 22, 2027 |
| patent | 12178824 | Jun 24, 2041 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Millicent US, Inc. | Jul 15, 2026 | Sep 3, 2026 | |
| Northstar Rx LLC | Jul 15, 2026 | Sep 3, 2026 | |
| Dr. Reddys Laboratories Inc. | Jul 15, 2026 | Sep 2, 2026 | |
| Dr.Reddy's Laboratories Inc. | Jul 15, 2026 | Sep 2, 2026 | |
| Patheon Inc. | Jul 15, 2026 | Sep 2, 2026 | |
| Mayne Pharma Inc. | Jul 15, 2026 | Aug 31, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Femlyv — NDC 72495-0601-84," retrieved September 3, 2026, https://drugdashboards.com/drug/72495060184.
Free to cite with attribution — see how the data is put together.